Genetic variability in key genes in prostaglandin e2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Pereira, Carina ^a,b,c   Queiroś, Sara ^a   Galaghar, Ana ^a   Sousa, Hugo ^a   Pimentel Nunes, Pedro ^a,d   Brandão, Catarina ^a   Moreira Dias, Luís ^a   Medeiros, Rui ^a,b,c,e   Dinis Ribeiro, Mário ^a,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Portuguese League Against Cancer (Norte)   (Portugal)

^d University of Porto   (Portugal)

^e UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYCLOOXYGENASE 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; PROSTAGLANDIN E2; PROSTAGLANDIN TRANSPORTER; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; ABCC4 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; PTGS2 PROTEIN, HUMAN; SLCO2A1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ABCC4 GENE; ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; COX 2 GENE; FEMALE; GENE AMPLIFICATION; GENETIC CODE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; HOMOZYGOSITY; HPGD GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO2A1 GENE; SMOKING HABIT; BIOLOGICAL MODEL; BIOSYNTHESIS; CLINICAL TRIAL; COLORECTAL TUMOR; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MALE; MIDDLE AGED; MODELS, GENETIC; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898827962     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092000     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; Available from: http://globocan.iarc.fr.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global Cancer Statistics. CA Cancer J Clin 61: 69-90.
3. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, et al. (2010) Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116: 544-573.
4. Gimeno Garcia AZ (2012) Factors influencing colorectal cancer screening participation. Gastroenterol Res Pract 2012: 483417.
5. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603-1613. (Pubitemid 46710123)
6. Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomized trials. Lancet Oncol 13(5): 518-527.
7. Vane JR, Blotting RM (1998) Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 104(3A): 2S-8S. (Pubitemid 28186987)
8. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, et al. (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188. (Pubitemid 24294584)
9. Wang D, Mann JR, Dubois RN (2005) The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128: 1445-1461. (Pubitemid 40712194)
10. Tai HH, Ensor CM, Tong M, Zhou H, Yan F (2002) Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 68-69: 483-493. (Pubitemid 35247416)
11. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, et al. (2005) 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280: 3217-3223. (Pubitemid 40223783)
12. Myung SJ, Rerko RM, Yan M, Buchanan FG, Tai HH, et al. (2006) 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci 103(32): 12098-12102. (Pubitemid 44215817)
13. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, et al. (2009) 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to Celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci 106(23): 9409-9413.
14. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, et al. (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci 100(16): 9244-9249. (Pubitemid 37033914)
15. Schuster VL (2002). Prostaglandin transport. Prostaglandins Other Lipid Mediat 68-69: 633-647.
16. Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN (2008) Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res 1(2): 93-99.
17. Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348(10): 919-932. (Pubitemid 36298000)
18. Pereira C, Medeiros R, Dinis-Ribeiro M (2009) Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol 21: 76-91.
19. Pereira C, Pimentel-Nunes P, Brandão C, Moreira-Dias L, Medeiros R, et al. (2010) COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol 22(5): 607-663.
20. Hoeft B, Linseisen J, Beckmann L, Muller-Decker K, Canzian F, et al. (2010) Polymorphisms in fatty acid metabolism-related genes are associated with colorectal cancer risk. Carcinogenesis 31(3): 466-472.
21. Thompson CL, Fink SP, Lutterbaugh JD, Elston RC, Veigl ML, et al. (2013) Genetic variation in 15-Hydroxyprostaglandin dehydrogenase and colon cancer susceptibility. PLoS One 8(5): e64122.
22. Abulí A, Fernández-Rozadilla C, Giráldez MD, Munõz J, Gonzalo V, et al. (2011) A two-phase case-control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22. BJC 105: 870-875.
23. Wacholder S, Chanock S, Garcia-Closas M, Rothman N (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96: 434-442. (Pubitemid 38443646)
24. Rodríguez LA, Tolosa LB (2009) Risk of upper gastrointestinal complications among users of Traditional NSAIDs and COXIBs in the general population. Gastroenterology 132(2): 4498-4506.
25. Liu F, Pan K, Zhang X, Zhang Y, Zhang L, et al. (2006) Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 130: 1975-1984. (Pubitemid 43816953)
26. Zhang X, Miao X, Tan W, Ning B, Liu Z, et al. (2005) Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129: 565-576. (Pubitemid 41096644)
27. Tan W, Wu J, Zhang X, Guo Y, Liu J, et al. (2007) Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 28: 1197-1201. (Pubitemid 47064309)
28. Ueda N, Maehara Y, Tajima O, Tabata S, Wakabayashi K, et al. (2008) Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: The Self Defense Forces Health Study. Cancer Sci 99: 576-581. (Pubitemid 351228576)
29. Peters WH, te Morsche RH, Roelofs HM, Mathus-Vliegen EM, Berhout M, et al. (2009) COX-2 polymorphisms in patients with familial adenomatous polyposis. Oncol Res 17: 347-351.
30. Pereira C, Sousa H, Silva J, Brandão C, Elgueta-Karstegl C, et al. (2013) The 2 1195G allele increases the transcriptional activity of cyclooxygenase-2 gene (COX-2) in colon cancer cell lines. Mol Carcinog. doi: 10.1002/mc.22049.
31. Sakaki M, Makino R, Hiroishi K, Ueda K, Eguchi J, et al. (2010) Cyclooxygenase-2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression. Hepatol Res 40: 1219-1226.
32. Martey CA, Pollock SJ, Turner CK, O'Reilly KM, Baglole CJ, et al. (2004) Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 287: L981-L991. (Pubitemid 39391028)
33. Wong HP, Yu L, Lam EK, Tai EK, Wu WK, et al. (2007) Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol Sci 97: 279-287. (Pubitemid 47073845)
34. Yan Z, Subbaramaiah K, Camilli T, Zhang F, Tanabe T, et al. (2000) Benzo[a]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. Evidence for the involvement of extracellular signal-regulated kinase and NF-kappaB. J Biol Chem 275: 4949-4955. (Pubitemid 30108890)
35. Moore AE, Young LE, Dixon DA (2012) A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts micro-RNA-mediated regulation. Oncogene 31(12): 1592-1598.
36. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356: 2131-2142. (Pubitemid 47010839)
37. Frank B, Hoeft B, Hoffmeister M, Linseisen J, Breitling LP, et al. (2010) Association of hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) variants and colorectal cancer risk. Carcinogenesis 32(2): 190-196.
38. Sinibaldi L, Harifi G, Bottillo I, Iannicelli M, El Hassani S, et al. (2010) A novel homozygous splice site mutation in the HPGD gene causes mild primary hypertrophic osteoarthropathy. Clin Exp Rheumatol 28(2): 153-157.